Amino-terminal Protein-protein Interaction Motif (POZ-domain) is Responsible for Activities of the Promyelocytic Leukemia Zinc Finger-retinoic Acid Receptor-alpha Fusion Protein
Overview
Authors
Affiliations
Promyelocytic leukemia zinc finger-retinoic acid receptor a (PLZF-RARalpha), a fusion receptor generated as a result of a variant t(11;17) chromosomal translocation that occurs in a small subset of acute promyelocytic leukemia (APL) patients, has been shown to display a dominant-negative effect against the wild-type RARalpha/retinoid X receptor alpha (RXRalpha). We now show that its N-terminal region (called the POZ-domain), which mediates protein-protein interaction as well as specific nuclear localization of the wild-type PLZF and chimeric PLZF-RARalpha proteins, is primarily responsible for this activity. To further investigate the mechanisms of PLZF-RARalpha action, we have also studied its ligand-receptor, protein-protein, and protein-DNA interaction properties and compared them with those of the promyelocytic leukemia gene (PML)-RARalpha, which is expressed in the majority of APLs as a result of t(15;17) translocation. PLZF-RARalpha and PML-RARalpha have essentially the same ligand-binding affinities and can bind in vitro to retinoic acid response elements (RAREs) as homodimers or heterodimers with RXRalpha. PLZF-RARalpha homodimerization and heterodimerization with RXRalpha were primarily mediated by the POZ-domain and RARalpha sequence, respectively. Despite having identical RARalpha sequences, PLZF-RARalpha and PML-RARalpha homodimers recognized with different affinities distinct RAREs. Furthermore, PLZF-RARalpha could heterodimerize in vitro with the wild-type PLZF, suggesting that it may play a role in leukemogenesis by antagonizing actions of not only the retinoid receptors but also the wild-type PLZF and possibly other POZ-domain-containing regulators. These different protein-protein interactions and the target gene specificities of PLZF-RARalpha and PML-RARalpha may underlie, at least in part, the apparent resistance of APL with t(11;17) to differentiation effects of all-trans-retinoic acid.
Farooq T, Lin Q, She X, Chen T, Li Z, Yu L Front Plant Sci. 2022; 13:1040547.
PMID: 36452094 PMC: 9702342. DOI: 10.3389/fpls.2022.1040547.
Current views on the genetic landscape and management of variant acute promyelocytic leukemia.
Zhang X, Sun J, Yu W, Jin J Biomark Res. 2021; 9(1):33.
PMID: 33957999 PMC: 8101136. DOI: 10.1186/s40364-021-00284-x.
Zhang C, Gao H, Li R, Han D, Wang L, Wu J Mol Plant Pathol. 2018; 20(1):78-91.
PMID: 30113770 PMC: 6430474. DOI: 10.1111/mpp.12741.
NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.
Nichol J, Galbraith M, Kleinman C, Espinosa J, Miller Jr W Cell Rep. 2016; 14(12):2938-49.
PMID: 26997274 PMC: 4814328. DOI: 10.1016/j.celrep.2016.02.074.
Tatemichi Y, Shibazaki M, Yasuhira S, Kasai S, Tada H, Oikawa H Cancer Sci. 2015; 106(7):848-56.
PMID: 25891951 PMC: 4520636. DOI: 10.1111/cas.12680.